Cell-free DNA in Acute Stroke
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Stroke. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Switzerland
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
CANTO - Cell-free DNA in Acute Stroke
Overview
Cell-free DNA (cfDNA) is an important pro-inflammatory and prothrombotic mediator. With this study the investigators aim to gain new insights into the role of cfDNA in stroke and to perform a combined analysis of cfDNA in the hyperacute phase of the disease using blood and thrombus analyses. The main objectives are to analyse cfDNA in different stroke etiologies, to investigate the relationship between cfDNA and important procedural factors such as secondary embolisation and reperfusion outcomes, to analyse the correlation between blood and thrombus content of cfDNA and to investigate the specific source of cfDNA in distinct stroke subtypes.
Primary outcome measures
- Stroke Etiology [Time frame: at day 1]
Secondary outcome measures (5)
- Correlation cfDNA concentration and perfusion outcome [Time frame: at day 1]
- Correlation cfDNA concentration and secondary embolism [Time frame: at day 1]
- Correlation cfDNA concentration and thrombus fragmentation. [Time frame: at day 1]
- Measures of cfDNA as a marker of systemic inflammation [Time frame: at day 1]
- 90-day functional outcomes [Time frame: up to 3 month]
Eligibility criteria
Inclusion criteria
- Acute ischemic stroke due to large vessel occlusion (LVO) who require mechanical thrombectomy (detected in CT-Scan or MRI-Scan)
- 18 years of age
Exclusion criteria
- Patients currently undergoing immunological therapies.
- Patients with immunological diseases
- Patients with systemic infections at the time of admission
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Switzerland · 1 center
- University Hospital Basel — Basel
Identifiers
NCT: NCT06928675 · 2025-00235; ko24grosse2